Age, time living with diagnosed HIV infection, and self-rated health.

Citation for published version:
McGowan, JA, Sherr, L, Rodger, AJ, Fisher, M, Miners, A, Anderson, J, Johnson, MA, Elford, J, Collins, S, Hart, G, Phillips, AN, Speakman, A & Lampe, FC 2017, 'Age, time living with diagnosed HIV infection, and self-rated health.', *HIV Medicine*, vol. 18, no. 2. https://doi.org/10.1111/hiv.12398

Digital Object Identifier (DOI):
10.1111/hiv.12398

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
HIV Medicine

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Age, time living with diagnosed HIV infection, and self-rated health

JA McGowan,1 L Sherr,1 AJ Rodger,1 M Fisher,2† A Miners,3 J Anderson,4 MA Johnson,5 J Elford,6 S Collins,7 G Hart,1
AN Phillips,1 A Speakman1 and FC Lampe1 for the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group*

1Research Department of Infection and Population Health, University College London, London, UK, 2Brighton and Sussex University Hospitals NHS Trust, Brighton, UK, 3London School of Hygiene and Tropical Medicine, London, UK, 4Homerton University Hospital NHS Foundation Trust, London, UK, 5Royal Free London NHS Foundation Trust, London, UK, 6School of Health Sciences, City University, London, UK and 7HIV i-Base, London, UK

Objectives
An increasing proportion of people living with HIV are older adults, who may require specialized care. Adverse physical and psychological effects of HIV infection may be greatest among older people or those who have lived longer with HIV.

Methods
The ASTRA study is a cross-sectional questionnaire study of 3258 HIV-diagnosed adults (2248 men who have sex with men, 373 heterosexual men and 637 women) recruited from UK clinics in 2011–2012. Associations of age group with physical symptom distress (significant distress for at least one of 26 symptoms), depression and anxiety symptoms (scores \( \geq 10 \) on PHQ-9 and GAD-7, respectively), and health-related functional problems (problems on at least one of three domains of the Euroqol 5D-3L) were assessed, adjusting for time with diagnosed HIV infection, gender/sexual orientation and ethnicity.

Results
The age distribution of participants was: < 30 years, 5%; 30–39 years, 23%; 40–49 years, 43%; 50–59 years, 22%; and ≥ 60 years, 7%. Overall prevalences were: physical symptom distress, 56%; depression symptoms, 27%; anxiety symptoms, 22%; functional problems, 38%. No trend was found in the prevalence of physical symptom distress with age [adjusted odds ratio (OR) for trend across age groups, 0.96; 95% confidence interval (CI) 0.89, 1.04; \( P = 0.36 \)]. The prevalence of depression and anxiety symptoms decreased with age [adjusted OR 0.86 (95% CI 0.79, 0.94; \( P = 0.001 \)) and adjusted OR 0.85 (95% CI 0.77, 0.94; \( P = 0.001 \)), respectively], while that of functional problems increased (adjusted OR 1.28; 95% CI 1.17, 1.39; \( P < 0.001 \)). In contrast, a longer time with diagnosed HIV infection was strongly and independently associated with a higher prevalence of symptom distress, depression symptoms, anxiety symptoms, and functional problems (\( P < 0.001 \) for trends, adjusted analysis).

Conclusions
Among people living with HIV, although health-related functional problems were more common with older age, physical symptom distress was not, and mental health was more favourable. These results suggest that a longer time with diagnosed HIV infection, rather than age, is the dominating factor contributing to psychological morbidity and lower quality of life.

Keywords: ageing, anxiety, depression, HIV, symptoms, wellbeing.

Accepted 11 February 2016
Introduction

As a consequence of advances in treatment, people diagnosed with HIV infection have greatly improved life expectancy [1]. In the UK, an estimated 27% of people living with diagnosed HIV infection were aged 50 years or over in 2013; this percentage has doubled in the past decade [2], with newly diagnosed infections among older people doubling in the same time period [2]. The Joint United Nations Programme on HIV/AIDS (UNAIDS) surmised that, world-wide by 2013, 10% of people diagnosed with HIV infection were over 50 years old and that in high-income countries this was nearer a third [3]. Research into this population’s requirements and experiences is important [4–6]. However, few studies have examined the effect of older age on wellbeing in people living with HIV.

Symptom prevalence is high in people living with HIV even in the era of combination antiretroviral therapy (cART) [7,8]. It has been suggested that adverse physical and psychological effects of HIV infection may be greatest among older people [4]. Older people with HIV infection may have been living with the diagnosis for many years and may have ongoing health problems or disability related to HIV infection, in addition to the age-related morbidities common in the general population. HIV infection and/or treatment has been implicated in a number of chronic conditions generally prevalent among older people, including cardiovascular disease, dyslipidaemia and osteoporosis [9–11] and a high medication burden is common among older people living with HIV [12]. Immune activation and chronic inflammation are associated with HIV infection and may be more prevalent among older adults [13]. Later HIV diagnosis in older adults can result in a lower likelihood of achieving immune recovery with cART [6,14]. It is conceivable, therefore, that HIV infection and older age could have cumulative detrimental effects on health [15].

Depression is common among people living with HIV [16,17]. Although there is a perception that older people with HIV may be particularly vulnerable to depression as a consequence of issues such as stigma and lack of social support [4], the association between age and psychological symptoms among people with HIV is unclear [6,16,18,19]. Quality of life has been defined as ‘multidimensional in construct including physical, emotional, mental, social, and behavioural components’ [6] and has been found to be lower among older compared with younger people with HIV [17], but the role of psychological, physical and functional problems in this relationship is unclear.

As HIV infection is now a chronic condition, research into the impact of age on wellbeing is increasingly relevant to patient care. However, few studies have examined the association of both age and time since HIV diagnosis with self-rated health and symptoms. We examined these questions in the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) study, a multicentre study of people living with HIV in the UK. We have previously reported that the health-related quality-of-life utility score was lower among people with diagnosed HIV compared with the UK general population, accounting for major demographic factors [17]. The aim of this present analysis was to assess, among people with diagnosed HIV, the association of age with: (a) the prevalence of physical symptoms causing distress, (b) the prevalence of depression and anxiety symptoms and (c) the prevalence of health-related functional problems, taking into account time since HIV diagnosis and other demographic factors.

Methods

The ASTRA study recruited 3258 individuals diagnosed with HIV infection from eight HIV out-patient clinics in the UK from February 2011 to December 2012 (64% response rate). Participants completed a self-administered questionnaire on a range of socio-demographic, health, HIV-related and lifestyle issues, and the clinic-recorded viral load and CD4 count were documented. Further details have been published [20].

In this analysis, information on physical symptoms, depression and anxiety symptoms, and health-related functional problems is reported in relation to age group, time with diagnosed HIV infection, gender/sexual orientation and ethnicity.

Symptom measures

Physical symptoms were quantified using a modified Memorial Symptom Assessment Scale-Short Form (MSAS-SF) scale [21], listing 26 common symptoms (Table 1). Participants were asked to report whether each symptom was present in the past 2 weeks, and, if so, to rank their distress on a four-point scale: ‘did not bother me’; ‘bothered/distressed a little bit’; ‘bothered/distressed quite a bit’; ‘bothered/distressed very much’. Symptoms were classified in two ways: ‘present’ (if the symptom was reported) and ‘distressing’ (if the symptom ‘bothered/distressed quite a bit’ or ‘very much’). ‘Physical symptom distress’ was defined as reporting at least one of the 26 symptoms as distressing. Several symptom subgroups were considered (Table 1) where participants were classified as positive if they reported at least one of the symptoms in that category as distressing.

Depression symptoms and anxiety symptoms were measured using standard symptom inventories (the Patient Health Questionnaire, 9 item scale (PHQ-9) [22]
Table 1 Prevalence of 26 physical symptoms and physical symptom distress in the past 2 weeks in the study participants (N = 3258)

| Symptom                                      | Present n (%) | Distressing n (%) | % of 'present' |
|----------------------------------------------|---------------|-------------------|---------------|
| Lack of energy                               | 2116 (64.9)   | 844 (25.9)        | 39.9          |
| Feeling drowsy/tired                         | 2105 (64.6)   | 790 (24.2)        | 37.5          |
| Difficulty sleeping                          | 1880 (58.0)   | 796 (24.4)        | 42.1          |
| Muscles aches or joint pains                 | 1740 (53.4)   | 678 (20.8)        | 39.0          |
| Trouble remembering things                  | 1676 (51.4)   | 569 (17.5)        | 33.9          |
| Problems with sexual interest/activity       | 1530 (47.0)   | 627 (19.2)        | 41.0          |
| Difficulty concentrating                     | 1514 (46.5)   | 462 (14.2)        | 30.5          |
| Skin problems (e.g. rash, itching or dryness)| 1375 (42.2)   | 430 (13.2)        | 31.3          |
| Numbness, tingling or pain in hands or feet  | 1338 (41.1)   | 514 (15.8)        | 38.4          |
| Headache                                     | 1294 (39.7)   | 343 (10.5)        | 26.5          |
| Pain                                         | 1282 (39.3)   | 586 (18.0)        | 45.7          |
| Feeling bloated                              | 1253 (38.5)   | 366 (11.2)        | 29.2          |
| Diarrhoea                                    | 1201 (36.9)   | 358 (11.0)        | 29.8          |
| Sweats/fever                                 | 1192 (36.6)   | 412 (12.6)        | 34.6          |
| Shortness of breath                          | 1056 (32.4)   | 340 (10.4)        | 32.2          |
| Cough                                        | 981 (30.1)    | 242 (7.4)         | 24.7          |
| Dry mouth                                    | 970 (29.8)    | 226 (6.9)         | 23.3          |
| Dizziness                                    | 961 (29.5)    | 293 (9.0)         | 27.8          |
| Changes in fat in face or body               | 947 (29.1)    | 248 (7.6)         | 26.0          |
| Nausea                                       | 811 (24.9)    | 221 (6.8)         | 27.3          |
| Lack of appetite                             | 754 (23.1)    | 204 (6.3)         | 27.1          |
| Constipation                                 | 663 (20.3)    | 199 (6.1)         | 30.0          |
| Changes in way food tastes                   | 564 (17.3)    | 159 (4.9)         | 28.2          |
| Weight loss                                  | 543 (16.7)    | 191 (5.9)         | 35.2          |
| Mouth sores                                  | 531 (16.3)    | 155 (4.8)         | 29.2          |
| Vomiting                                     | 392 (12.0)    | 125 (3.8)         | 31.9          |
| Combined symptom categories                  |               |                   |               |
| Sleep/energy/tiredness problems*             | 2522 (77.4)   | 1140 (35.0)       | 45.2          |
| Concentration/memory problems†               | 1927 (59.1)   | 736 (22.6)        | 38.2          |
| Pain/headache                                | 1746 (53.6)   | 688 (21.1)        | 39.4          |
| Gastrointestinal symptoms§                   | 1986 (61.0)   | 704 (21.6)        | 35.4          |

*Includes ‘lack of energy’, ‘feeling drowsy/tired’ and ‘difficulty sleeping’.
†Includes ‘trouble remembering things’ and ‘difficulty concentrating’.
‡Includes ‘pain’ and ‘headache’.
§Includes ‘feeling bloated’, ‘diarrhoea’, ‘nausea’, ‘constipation’ and ‘vomiting’.
’Symptom causes ‘quite a bit of’ or ‘very much’ distress.

and Generalized Anxiety Disorder 7 item scale (GAD-7) [23]) that inquire about the frequency of occurrence of specific symptoms in the past 2 weeks: depression and anxiety were defined according to standard algorithms based on a total score of 10 or more in each case.

A ‘health-related functional problem’ was defined as reporting ‘some’ or ‘severe’ problems (rather than ‘no problems’) on one of three functional domains (mobility, self-care and daily activities) of a standard health-related quality of life (HRQoL) measure, the Euroqol 5D 3L (EQ-5D-3L) [24]. In addition, the three domains of the EQ-5D-3L were considered separately.

Missing values for individual questions on symptom/HRQoL questionnaires were counted as the absence of symptoms. PHQ-9, GAD-7, modified MSAS-SF and the three domains of the EQ-5D-3L are shown in Appendix 2. Of note, both PHQ-9 and modified MSAS-SF incorporate questions on tiredness, sleep, appetite and concentration.

Statistical analysis

Age was grouped as follows: < 30, 30–39, 40–49, 50–59 and ≥ 60 years. Differences in participant characteristics by age group were assessed using χ² tests for trend.

Prevalences of physical symptom distress, depression, anxiety and health-related functional problems were calculated overall and by age group. Logistic regression was used to test the association between age group and each of the health measures (dependent variables), adjusting for gender/sexual orientation [men who have sex with men (MSM), heterosexual men and women], ethnicity [white and nonwhite/missing] and years with diagnosed HIV infection [< 2, 2–<5, 5–<10, 10–<15, 15–<20 and ≥ 20 years]. Age was fitted as a categorical variable in the models. Tests for linear trend across categories were also performed for age and years with diagnosed HIV infection. Results are presented as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance was assessed using likelihood ratio tests. Sensitivity analyses: (i) treating age and years with diagnosed HIV infection as continuous rather than categorical variables (ii) additionally adjusting for university education and (iii) additionally adjusting for clinical centre yielded the same conclusions regarding trends (data not shown).

Results

Subject characteristics

Of the 3258 study participants, 2248 (69.0%) were MSM, 373 (11.4%) were heterosexual men and 637 (19.6%) were women. The mean age was 45 years (standard deviation 9.6 years; range 18–88 years). Of 3190 participants with age information, 172 (5.4%) were under 30 years old, 745 (23.4%) 30–39 years old, 1370 (42.9%) 40–49 years old, 689 (21.6%) 50–59 years old and 214 (6.7%) ≥ 60 years old. Time since diagnosis of HIV infection (n = 3230) was: 0–2 years for 373 patients (11.5%), 2–5 years for 498 (15.4%), 5–10 years for 893 (27.6%), 10–15 years for 647 (20.0%), 15–20 years for 488 (15.1%) and ≥ 20 years for 331 (10.2%). In terms of ethnic origin, 2220 (68.1%) participants were white, 614 (18.8%) were of black African ethnicity, 125 (3.8%) were of other black ethnicity and 299 (9.2%) were of other/missing ethnicity; 56.1% (1785 of 3183) of all partici-
pants were born in the UK. Over half of participants (1821 of 3174; 57.4%) were employed, 577 (18.2%) were unemployed. 420 (13.2%) were not working because of sickness/disability, 192 (6.0%) were retired, and 164 (5.2%) were students, took care of the home, or other. A high proportion of participants were university educated (1317; 40.4%). Overall, 86.5% (2771 of 3202) of participants were on ART, 76.2% (2466 of 3237) had viral load (VL) ≤ 50 HIV-1 RNA copies/mL and 18.5% (599 of 3235) had CD4 count < 350 cells/µL.

Older participants were more likely to be male (88.8% for age ≥ 60 years vs. 68.6% for age < 30 years; P < 0.001, χ² test for trend across all age groups), of white ethnicity (77.1% vs. 58.1%, respectively; P < 0.001), to have been born in the UK (70.0% vs. 51.5%, respectively; P < 0.001), to have been diagnosed with HIV infection for more than 10 years (63.0% vs. 53.3%, respectively; P < 0.001), to be on ART (93.8% vs. 60.9%, respectively; P < 0.001) and to have VL ≤ 50 copies/mL (88.7% vs. 48.8%, respectively; P < 0.001). Older people were less likely to be employed (19.7% vs. 60.9% for age ≥ 60 years vs. < 30 years, respectively; P < 0.001). No significant trend with age was found for university education (33.6% vs. 35.5%, respectively; P = 0.11) or CD4 count < 350 cells/µL (19.3% vs. 23.4%, respectively; P = 0.69).

Physical symptom distress

Table 1 reports the prevalence of each symptom according to whether it was (i) present and (ii) distressing. At least one symptom was reported as ‘distressing’ by 55.6% of participants (1811 of 3258), while 11.0% reported ten or more distressing symptoms. The five most prevalent distressing symptoms were ‘lack of energy’ (25.9%), ‘difficulty sleeping’ (24.4%), ‘feeling drowsy/tired’ (24.2%), ‘muscle aches or joint pains’ (20.8%) and ‘problems with sexual interest/activity’ (19.2%). Although lower in prevalence, ‘pain’ and ‘changes in fat’ were more likely to cause distress when present than other symptoms.

The three most prevalent distressing symptoms within age groups were the same for each of the four age groups under 60 years: ‘lack of energy’ (22.1–30.9%), followed by ‘feeling drowsy/tired’ (20.0–28.4%) and ‘difficulty sleeping’ (21.7–26.7%), and the proportion who reported no distressing symptoms ranged from 38.8% to 48.6%. Among participants aged ≥ 60 years the pattern was different: ‘muscle ache/joint pains’ was the most prevalent distressing symptom (23.8%), followed by ‘pain’ (18.2%) and ‘lack of energy’ (18.2%), but 47.7% of participants reported no distressing symptoms.

Figure 1a shows the prevalence of physical symptom distress overall and for selected common symptoms and symptom subgroups by age group. The prevalence of overall symptom distress tended to increase slightly with age over the 30–59-year age range, but was lower in the ≥ 60-year age group. Interestingly, participants aged < 30 years tended to have a higher prevalence of distressing symptoms compared with those aged 30–40 years, and compared with the ≥ 60-year age group. Most of the symptom groups followed this pattern, with ‘muscle-ache/joint pain’, ‘numbness/tingling/pain in the hands/feet’ and ‘pain’ having the strongest increases with age.

The adjusted association of age with physical symptom distress is presented in Table 2. After adjustment for gender/sexual orientation, time with diagnosed HIV infection and ethnicity, there was no trend with age group in the prevalence of overall physical symptom distress. For ‘numbness/tingling/pain in the hands or feet’ and ‘muscle ache/joint pain’, however, there was a significant increase in prevalence with age, while for ‘problems with sexual interest/activity’ there was a significant decrease with age. However, for all symptom groups, the prevalence of distressing symptoms was lower among those aged ≥ 60 years than those aged 50–60 years. In fact, for many symptom groups, participants aged ≥ 60 years had the lowest prevalence of distressing symptoms overall.

Time with diagnosed HIV infection was strongly related to the prevalence of overall physical symptom distress and each symptom subgroup: those diagnosed for longer were more likely to report distressing symptoms (test for trend across categories P < 0.001 for overall symptom distress and all symptom measures in adjusted models, Table 2). There were also differences by gender/sexual orientation. For many symptom subgroups, the pattern was similar: compared with MSM, the prevalence of distressing symptoms tended to be somewhat lower among heterosexual men, and somewhat higher among women. There were few significant differences according to ethnicity.

Psychological symptoms

Depression (assessed using PHQ-9) was apparent in 27.1% (884 of 3258) of participants and anxiety (assessed using GAD-7) in 21.9% (715 of 3258). Figure 1b shows the associations with age. The prevalence of symptoms of depression tended to decrease with age, being highest in the < 30-year age group, similar across the three age groups from 30 to 59 years, and lowest in those aged ≥ 60 years. The prevalence of anxiety also tended to decrease with age, following a similar pattern and being lowest among the ≥ 60-year age group. These patterns of decreasing prevalence with age were stronger in the adjusted analysis (Table 3). However, in contrast to older age, longer time
Prevalence of distressing physical symptoms (%) by age.

Prevalence of depression and anxiety symptoms (%) by age.

Prevalence of health-related functional problems (%) by age.

Fig. 1 Prevalences (%) of (a) distressing physical symptoms, (b) depression and anxiety symptoms, and (c) health-related functional problems by age group. Physical symptom distress was defined using modified MSAS-SF (see Table 1); depression symptoms were defined as a PHQ-9 score ≥ 10; anxiety symptoms were defined as a GAD-7 score ≥ 10; health-related functional problems were defined using the three domains of Euroqol 5D 3. N = 3190 participants with information on age.
### Table 2 Adjusted association of age, time with diagnosed HIV infection, gender/sexual orientation and ethnicity with physical symptom distress (*N* = 3167)

| Independent variable | Physical symptom distress | Sleep/energy/tiredness problems | Concentration/memory problems | Gastrointestinal symptoms | Pain/headache |
|----------------------|---------------------------|---------------------------------|-------------------------------|--------------------------|--------------|
|                      | Adjusted odds ratio† 95% CI | Adjusted odds ratio† 95% CI | Adjusted odds ratio† 95% CI | Adjusted odds ratio† 95% CI | Adjusted odds ratio† 95% CI |
| **Age**              |                           |                                |                               |                          |              |
| < 30 years            | 1.84 (1.20, 2.82)         | 2.36 (1.49, 3.76)              | 2.04 (1.22, 3.41)             | 2.15 (1.25, 3.68)        | 0.08         |
| 30–39 years           | 1.23 (0.89, 1.69)         | 1.74 (1.21, 2.51)              | 1.33 (0.88, 2.01)             | 1.40 (0.91, 2.14)        | 0.87         |
| 40–49 years           | 1.25 (0.93, 1.68)         | 1.91 (1.36, 2.67)              | 1.42 (0.97, 2.08)             | 1.60 (1.08, 2.37)        | 1.13         |
| 50–59 years           | 1.46 (1.06, 2.01)         | 2.08 (1.46, 2.95)              | 1.67 (1.12, 2.47)             | 1.98 (1.31, 2.97)        | 1.44         |
| ≥ 60 years            |                           |                                |                               |                          |              |
| Test for trend†       | 0.36 (0.89, 1.04)         | 0.08 (0.85, 1.01)              | 0.42 (0.87, 1.06)             | 0.77 (0.89, 1.09)        | 0.70         |
| **Years with diagnosed HIV infection** | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| 0–2 years‡            | 1.08 (0.82, 1.41)         | 1.12 (0.82, 1.51)              | 1.14 (0.80, 1.64)             | 1.05 (0.72, 1.53)        | 1.35         |
| 2–5 years             | 1.13 (0.89, 1.45)         | 1.33 (1.01, 1.79)              | 1.48 (1.07, 2.03)             | 1.49 (1.07, 2.09)        | 1.67         |
| 5–10 years            | 1.35 (1.04, 1.76)         | 1.59 (1.19, 2.12)              | 1.40 (0.99, 1.96)             | 1.72 (1.21, 2.44)        | 1.82         |
| 10–15 years           | 1.86 (1.39, 2.47)         | 1.97 (1.45, 2.68)              | 1.91 (1.34, 2.71)             | 2.05 (1.43, 2.95)        | 2.47         |
| 15–20 years           | 2.73 (1.96, 3.79)         | 2.72 (1.95, 3.80)              | 2.52 (1.73, 3.66)             | 2.41 (1.64, 3.55)        | 3.58         |
| ≥ 20 years            |                           |                                |                               |                          |              |
| Test for trend‡       | < 0.001                   | < 0.001                        | < 0.001                       | < 0.001                  | < 0.001      |
| **Gender/sexual orientation** | 0.047 | 0.11    | 0.022  | 0.005   |              |
| MSM                  |                           |                                |                               |                          |              |
| Heterosexual men     | 0.75 (0.58, 0.97)         | 0.75 (0.57, 0.99)              | 0.89 (0.65, 1.22)             | 0.63 (0.44, 0.89)        | 0.72         |
| Women                | 1.02 (0.81, 1.28)         | 0.97 (0.76, 1.23)              | 1.37 (1.06, 1.78)             | 1.17 (0.89, 1.54)        | 1.28         |
| **Ethnicity**        |                           |                                |                               |                          |              |
| White                 | 0.77 (0.58, 0.97)         | 0.75 (0.57, 0.99)              | 0.89 (0.65, 1.22)             | 0.63 (0.44, 0.89)        | 0.72         |
| Other ethnicity       | 1.03 (0.84, 1.26)         | 0.87 (0.70, 1.07)              | 1.16 (0.92, 1.47)             | 0.81 (0.63, 1.04)        | 1.41         |
|                      |                           |                                |                               |                          |              |
| **Sexual interest/activity problems** | 0.041 | 0.001  | 0.15  | 0.001 | 0.001 |
| Age                  | 2.18 (1.23, 3.85)         | 0.85 (0.50, 1.48)              | 1.56 (0.79, 3.08)             | 0.65 (0.34, 1.24)        |              |
| 30–39 years           | 1.70 (1.09, 2.66)         | 0.70 (0.47, 1.04)              | 1.26 (0.75, 2.12)             | 0.68 (0.44, 1.06)        |              |
| 40–49 years           | 1.81 (1.19, 2.74)         | 0.87 (0.61, 1.24)              | 1.40 (0.87, 2.25)             | 0.90 (0.61, 1.33)        |              |
| 50–59 years           | 1.66 (1.07, 2.55)         | 1.27 (0.88, 1.82)              | 1.71 (1.05, 2.79)             | 1.30 (0.87, 1.93)        |              |
| ≥ 60 years†           | 1.97 (1.34, 2.90)         | 1.66 (1.07, 2.55)              | 1.27 (0.88, 1.82)             | 1.71 (1.05, 2.79)        | 1.30         |
| Test for trend‡       | 0.32 (0.81, 0.99)         | 0.001 (1.07, 1.31)             | 0.80 (0.90, 1.15)             | < 0.001                  | 1.22         |
| **Years with diagnosed HIV infection** | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| 0–2 years‡            | 1.34 (0.91, 1.97)         | 1.45 (0.95, 2.20)              | 0.79 (0.48, 1.30)             | 1.37 (0.84, 2.21)        |              |
| 2–5 years             | 1.43 (1.00, 2.04)         | 1.84 (1.26, 2.69)              | 1.31 (0.86, 1.98)             | 1.81 (1.18, 2.78)        |              |
| 5–10 years            | 1.85 (1.28, 2.67)         | 2.20 (1.50, 3.25)              | 1.58 (1.02, 2.44)             | 2.46 (1.59, 3.81)        |              |
| 10–15 years           | 1.97 (1.34, 2.90)         | 3.09 (2.07, 4.60)              | 2.58 (1.66, 4.00)             | 2.62 (1.67, 4.11)        |              |
| 15–20 years           |                           |                                |                               |                          |              |
with diagnosed HIV infection was strongly associated with a higher prevalence of both depression and anxiety ($P < 0.001$, for trend across categories for each in adjusted models). There were no significant differences according to gender/sexual orientation or ethnicity.

**Health-related functional problems**

The prevalence of health-related functional problems was 38.1% (1240 of 3258) overall and the prevalence of individual domains was: mobility problems, 27.1%; self-care problems, 12.3%; and problems performing usual activity, 32.1%. Few participants ($< 3\%$) reported 'extreme' problems with mobility, self-care or usual activities. Figure 1c shows that the prevalence of health-related functional problems tended to increase with age for the overall measure and all three domains.

Table 4 shows that patterns were similar in adjusted analysis. The prevalence of functional problems significantly increased with age. As was the case for the physical and psychological symptom measures, longer time since HIV diagnosis was strongly associated with a greater prevalence of functional problems, both overall and for each domain ($P < 0.001$ for trend across categories in adjusted models). In addition, mobility problems tended to be more common among women compared with MSM. There were no significant differences by ethnicity.

**Discussion**

In this large multicentre cross-sectional UK study, with older age, people living with HIV reported a higher prevalence of health-related functional problems, but a lower prevalence of depression and anxiety symptoms. There was no trend with age in the prevalence of overall physical symptom distress, but the pattern varied according to the specific symptom. Longer time with diagnosed HIV infection, however, was related to a higher prevalence of all self-rated health problems: symptom distress, depression, anxiety and each domain of functional problems, independently of age.

In our study, as found in the international START (Strategic Timing of AntiRetroviral Treatment) trial population at baseline, [25], the prevalence of problems with physical mobility and daily function (assessed using the EQ-5D-3L) increased with age, probably as a result primarily of an increasing prevalence of chronic illness and disability. Age was not significantly associated with overall physical symptom distress, but prevalence did increase with age for specific symptom groups (muscle ache/joint pain, and numbness/tingling/pain in hands or...
feet). However, we found a lower prevalence of distressing symptoms in the over-60s group compared with younger age groups, both overall and for many symptom subgroups. This could, in part, be attributable to older adults attributing health changes to natural ageing and therefore not rating them as distressing [26,27]. Previous research also posits that older adults may face fewer high-demand situations as a consequence of retirement, leaving increased time and mental reserves for coping with physical distress [28]. It could also reflect ‘resilience’ in older HIV-diagnosed people, lower expectations of good health, or greater tolerance of poor health function [29].

In terms of mental health, the prevalence of depression and anxiety, assessed using standardized symptom questionnaires, tended to decrease with age, a trend that became more marked after adjustment for time with diagnosed HIV infection. In particular, the prevalences of depression and anxiety were lower in the over-60s compared with all other age groups. Interestingly, when analysed by individual questions, the decreasing prevalence with age was more apparent for ‘psychological’ symptoms of depression such as ‘feeling down’ or ‘thoughts you would be better off dead’, than for ‘physical’ symptoms of depression, such as ‘feeling tired’ or ‘appetite problems’ (data on request). It is possible that deteriorating physical health in older age, or ageing with HIV infection, in addition to depression contributes to these ‘physical’ symptoms [30], or that in older adults depression is defined more often by somatic, rather than psychological, symptoms [31]. It has been suggested that the burden of psychological symptoms is high among older people living with HIV [6,32,33], although few studies have assessed the association between age and anxiety. Our results showed a lower prevalence of psychological symptoms among older people living with HIV, which could be mediated by improved social, behavioural or economic circumstances in the older population (such as reduced recreational drug use). It is possible that the lower prevalences of anxiety and depression among older compared with younger people living with HIV reflect better adaptation to hardship in older adults, developed through their lifespan [34,35], or ‘resilience’ [36], which has been found to be high in older HIV-diagnosed people [28,37]. Alternatively, this could be an example of ‘successful ageing’ in HIV-diagnosed people; the ability to maintain mental health despite age-related health losses [37]. However, it could also reflect a ‘survivor’ selection effect towards psychological wellbeing.

The overall prevalence of health-related functional problems, as assessed by three domains of the EQ-5D-3L,
Table 4 Adjusted association of age, time with diagnosed HIV infection, gender/sexual orientation and ethnicity with health-related function problems \((N = 3167)\)

| Independent variable | Mobility problems | Self-care problems | Usual activities problems |
|----------------------|-------------------|--------------------|-------------------------|
|                      | Adjusted odds ratio† | 95% CI | Adjusted odds ratio† | 95% CI | Adjusted odds ratio† | 95% CI | Adjusted odds ratio† | 95% CI |
| **Age**              |                   |       |                   |       |                   |       |                   |       |
| <30 years            | 0.39 (0.24, 0.65) | 0.37 (0.15, 0.92) | 0.39 (0.24, 0.65) | 0.37 (0.15, 0.92) | 0.39 (0.24, 0.65) | 0.37 (0.15, 0.92) |
| 30–39 years          | 0.22 (0.15, 0.32) | 0.53 (0.33, 0.86) | 0.22 (0.15, 0.32) | 0.53 (0.33, 0.86) | 0.22 (0.15, 0.32) | 0.53 (0.33, 0.86) |
| 40–49 years          | 0.45 (0.33, 0.61) | 0.87 (0.59, 1.30) | 0.45 (0.33, 0.61) | 0.87 (0.59, 1.30) | 0.45 (0.33, 0.61) | 0.87 (0.59, 1.30) |
| 50–59 years          | 0.73 (0.53, 1.00) | 1.00 (0.66, 1.51) | 0.73 (0.53, 1.00) | 1.00 (0.66, 1.51) | 0.73 (0.53, 1.00) | 1.00 (0.66, 1.51) |
| ≥60 years §          | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) |
| Test for trend ‡     | 1.28 (1.17, 1.39) | 1.54 (1.40, 1.70) | 1.28 (1.17, 1.39) | 1.54 (1.40, 1.70) | 1.28 (1.17, 1.39) | 1.54 (1.40, 1.70) |
| **Years with diagnosed HIV infection** |                   |       |                   |       |                   |       |                   |       |
| 0–2 years §          | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) |
| 2–5 years            | 1.23 (0.83, 1.84) | 1.29 (0.65, 2.55) | 1.23 (0.83, 1.84) | 1.29 (0.65, 2.55) | 1.23 (0.83, 1.84) | 1.29 (0.65, 2.55) |
| 5–10 years           | 1.81 (1.28, 2.57) | 2.92 (1.64, 5.21) | 1.81 (1.28, 2.57) | 2.92 (1.64, 5.21) | 1.81 (1.28, 2.57) | 2.92 (1.64, 5.21) |
| 10–15 years          | 2.45 (1.71, 3.50) | 3.14 (1.74, 5.65) | 2.45 (1.71, 3.50) | 3.14 (1.74, 5.65) | 2.45 (1.71, 3.50) | 3.14 (1.74, 5.65) |
| 15–20 years          | 4.04 (2.80, 5.82) | 4.99 (2.77, 9.00) | 4.04 (2.80, 5.82) | 4.99 (2.77, 9.00) | 4.04 (2.80, 5.82) | 4.99 (2.77, 9.00) |
| ≥20 years            | 5.05 (3.42, 7.44) | 6.88 (3.77, 12.56) | 5.05 (3.42, 7.44) | 6.88 (3.77, 12.56) | 5.05 (3.42, 7.44) | 6.88 (3.77, 12.56) |
| Test for trend ‡     | 1.36 (1.29, 1.44) | 1.42 (1.33, 1.51) | 1.36 (1.29, 1.44) | 1.42 (1.33, 1.51) | 1.36 (1.29, 1.44) | 1.42 (1.33, 1.51) |
| **Gender/sexual orientation** |                   |       |                   |       |                   |       |                   |       |
| MSM §                | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) |
| Heterosexual men     | 1.09 (0.81, 1.50) | 1.18 (0.80, 1.74) | 1.09 (0.81, 1.50) | 1.18 (0.80, 1.74) | 1.09 (0.81, 1.50) | 1.18 (0.80, 1.74) |
| Women                | 1.31 (1.01, 1.71) | 1.10 (0.77, 1.57) | 1.31 (1.01, 1.71) | 1.10 (0.77, 1.57) | 1.31 (1.01, 1.71) | 1.10 (0.77, 1.57) |
| **Ethnicity**        |                   |       |                   |       |                   |       |                   |       |
| White §              | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) | 1.00 (0.66, 1.51) |
| Other ethnicity      | 1.03 (0.83, 1.27) | 0.86 (0.63, 1.18) | 1.03 (0.83, 1.27) | 0.86 (0.63, 1.18) | 1.03 (0.83, 1.27) | 0.86 (0.63, 1.18) |

*Reports at least some difficulties with at least one of the three domains.
†Multivariable logistic regression model including all factors in table. P-values obtained using likelihood ratio test.
‡Linear trend across groups.
§Reference group.
CI, confidence interval; MSM, men who have sex with men.
Other ethnicity includes missing values.

© 2016 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association

HIV Medicine (2017), 18, 89–103
increased with age. Similar patterns of results were found in other cross-sectional studies. A study using the WHO-QOL-HIV [38] across eight (mainly low-income) countries found physical symptoms tended to be more common for older HIV-diagnosed people but mental health aspects were more favourable. Similarly, in the international START trial population, overall quality of life and the physical health component decreased with age, but the mental health component improved [25]. A multicentre US study found few differences by age in health-related quality of life among HIV-diagnosed people [18] using the HAT-Quality of Life scale, but in this scale daily function has a smaller role and psychosocial measures take precedence [39]. These results highlight the sensitivity of quality of life analyses to the specific instrument used, and weighting of domains within that instrument, and emphasize the importance of understanding contrasting trends across different health domains.

In contrast to older age, longer time with diagnosed HIV infection was strongly and independently related to poorer physical and psychological health across all measures studied, suggesting it may be a more important factor than chronological age in determining wellbeing among people living with HIV. The association between longer time with diagnosed HIV infection and poorer health is likely to be related to earlier calendar time of diagnosis: having been diagnosed at a time when HIV prognosis was poor, treatments were less effective or more complex, HIV-related stigma was greater, and companions and supportive networks may have been lost. However, it may also be related to increased time living with a chronic disease and its health and social implications, younger age at HIV diagnosis, the effects of prolonged HIV treatment, or the effect of longer time with untreated HIV infection specifically. The fact that, for most of the health measures, an association with time with diagnosed HIV infection was apparent even within the group diagnosed in the last ten years (from 2001/2002 to 2011/2012; a time of good prognosis) may give some support to the latter explanations as contributing factors. Future studies are needed to explore whether the strong effect of time with diagnosed HIV on health measures is related to ageing with HIV infection, or whether it primarily represents a historical effect of diagnosis in the pre-cART or early cART eras. Research assessing the effects on health of cumulative time with detectable vs undetectable viral load may also be valuable.

Studies assessing self-reported symptoms among people living with HIV are an important addition to those based on clinic data, as they provide information on health from the participant’s perspective. ASTRA is the largest questionnaire study of HIV-diagnosed individuals in the UK to date, and one of the few to examine associations of age with symptoms, having accounted for time with diagnosed HIV infection. However, our study has several limitations. We have previously compared health-related quality of life utility score (using EQ-5D-3L) between the ASTRA participants and a large UK general population sample [17], but unfortunately there is no corresponding contemporary information on the prevalence of symptoms assessed using PHQ-9/GAD-7/MSAS-SF from UK general population studies to compare with results for the ASTRA sample. The study response rate was 64% overall, but there may have been differential nonresponse according to age which could cause bias in the assessment of age trends. Very few of the participants had severe mobility problems, which may be correlated to the ability to attend the clinic, and so may exclude a group with very poor health. Grouping all adults over 60 years old together prevents us from identifying age differences within this subgroup.

We aimed to assess the association of age with self-reported health measures with adjustment for key demographic factors for which the causal direction of association would be uncontroversial. Socio-economic [40–42], HIV- and treatment-related [43,44], and lifestyle factors are worthy of future study as potential confounders or mediators of age effects.

**Implications**

This paper presents findings of age-related differences in wellbeing among people living with HIV and the independent effect of time with diagnosed HIV infection. Older people living with HIV are increasing in number globally [3] and health care systems will need to adapt to meet the needs of this ageing population. Quality of life, autonomy and self-rated health are essential components of successful ageing [34,45]; our findings should inform the development of appropriate services for older HIV-positive people. These data do not support the hypothesis that older compared with younger people living with HIV have a disproportionate burden of symptoms. As psychological health appeared to be better among older participants, further exploration of ‘successful ageing’ among people with HIV and the positive effects of age on coping would be of value.

However, the strong and consistent associations between longer time with diagnosed HIV infection and poorer self-reported health, even after accounting for age, suggest the need for supportive strategies for people who have lived with HIV for a long period of time (including those diagnosed in the pre-cART period, or as younger adults), and emphasize the importance of regular care,
and ongoing evaluation of psychological health, even for individuals who are virologically stable on ART. Independent associations of both older age and longer time since HIV diagnosis with physical health problems emphasize the importance of screening and assessment for age-related conditions among people under care for HIV infection, and prompt referral to suitable services.

For many symptom measures, we did not find continuous trends with age. Grouping older people together in an over-50s age group may miss important differences, such as possible improvements in symptom burden with older age. As the HIV-positive population ages, it will be important for future research to examine older age groups separately, as well as account for time since HIV diagnosis.

Acknowledgements

All ASTRA study participants and ASTRA clinic teams are thanked for taking part in the study.

Funding and support: The ASTRA study presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0608-10142). The ASTRA Study Group acknowledges the support of the NIHR, through the Comprehensive Clinical Research Network. The views expressed in this presentation are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Appendix 1: The ASTRA Study Group and Advisory Board

ASTRA clinic teams
Royal Free Hospital: Alison Rodger, Margaret Johnson, Jeff McDonnell and Adebiyi Aderonke. Mortimer Market Centre: Richard Gilson, Simon Edwards, Lewis Haddow, Simon Gilson, Christina Broussard, Robert Pralat and Sonali Wayal. Brighton and Sussex University Hospital: Martin Fisher, Nicky Perry, Alex Pollard, Serge Fedele, Louise Kerr, Lisa Heald, Wendy Hadley, Kerry Hobbs, Julia Williams, Elaney Yousef, Celia Richardson and Sean Groth. North Manchester General Hospital: Ed Wilkins, Yvonne Clowes, Jennifer Cullie, Cynthia Murphy, Christina Martin, Valerie George and Andrew Thompson. Homerton University Hospital: Jane Anderson, Sifiso Mguni, Damilola Awoiska and Rosalind Scourse. East Sussex Sexual Health Clinic: Kazeem Aderogba, Caron Osborne, Sue Cross, Jacqueline Whinney and Martin Jones. Newham University Hospital: Rebecca O’Connell and Cheryl Tawana. Whipps Cross University Hospital: Monica Lascar, Zandile Maseko, Gemma Townsend, Vera Theodore and Jas Sagoo.

ASTRA core team
Fiona Lampe, Alison Rodger, Andrew Speakman and Andrew Phillips.

ASTRA data management
Andrew Speakman, Marina Daskalopoulou and Fiona Lampe.

ASTRA advisory group
Lorraine Sherr, Simon Collins, Jonathan Elford, Alec Meners, Anne Johnson, Graham Hart, Anna-Maria Geretti and Bill Burman.

CAPRA grant advisory board
Nick Partridge, Kay Orton, Anthony Nardone and Ann Sullivan.
Appendix 2: Symptom questionnaires

Modified MSAS-SF

Below is a list of symptoms. Did you have any of these symptoms during the PAST 2 WEEKS? Please tick one box in each row to tell us whether you have had the symptom and, if so, how much it DISTRESSED or BOTHERED you.

| Did you have any of these symptoms during the PAST 2 WEEKS? | No did not have the symptom | Yes, had symptom but it DID NOT BOTHER ME | Yes, had symptom and was bothered/ distressed A LITTLE BIT | Yes, had symptom and was bothered/ distressed QUITE A BIT | Yes, had symptom and was bothered/ distressed VERY MUCH |
|------------------------------------------------------------|-----------------------------|-----------------------------------------|-------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------|
| 1. Difficulty concentrating                                | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 2. Difficulty sleeping                                     | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 3. Lack of energy                                          | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 4. Feeling drowsy/tired                                    | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 5. Trouble remembering things                              | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 6. Pain                                                    | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 7. Headache                                                | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 8. Numbness, tingling or pain in hands or feet             | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 9. Muscle aches or joint pains                             | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 10. Nausea                                                 | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 11. Vomiting                                               | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 12. Diarrhoea                                              | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 13. Constipation                                           | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 14. Feeling bloated                                        | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 15. Dizziness                                              | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 16. Sweats/fever                                           | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 17. Cough                                                  | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 18. Shortness of breath                                    | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 19. Problems with sexual interest/activity                 | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 20. Skin problems (e.g. rash, itching, dryness)            | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 21. Dry mouth                                              | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 22. Mouth sores                                            | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 23. Lack of appetite                                       | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 24. Changes in way food tastes                             | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 25. Weight loss                                            | □                           | □                                       | □                                                          | □                                                        | □                                                        |
| 26. Changes in fat in face or body                         | □                           | □                                       | □                                                          | □                                                        | □                                                        |

PHQ-9 and GAD-7

Over the PAST 2 WEEKS, how often have you been bothered by any of the following problems? Please tick one box in each row.

| PHQ-9                                                                 | Not at all | Several days | More than half the days | Nearly every day |
|-----------------------------------------------------------------------|------------|--------------|--------------------------|------------------|
| (1) Little interest or pleasure in doing things                       | □          | □            | □                        | □                |
| (2) Feeling down, depressed, or hopeless                               | □          | □            | □                        | □                |
| (3) Trouble falling or staying asleep, or sleeping too much            | □          | □            | □                        | □                |
| (4) Feeling tired or having little energy                              | □          | □            | □                        | □                |
| (5) Poor appetite or overeating                                       | □          | □            | □                        | □                |
| (6) Feeling bad about yourself—or that you are a failure or have let yourself or your family down | □          | □            | □                        | □                |

© 2016 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association  HIV Medicine (2017), 18, 89–103
EUROQOL 5D 3L – first three domains

Please indicate which statements best describes your own state of health TODAY. Please tick one box in each section

(a) Mobility
☐ I have no problems in walking about
☐ I have some problems in walking about
☐ I am confined to bed

(b) Self-care
☐ I have no problems with self-care
☐ I have some problems washing or dressing myself
☐ I am unable to wash or dress myself

(c) Usual activities (e.g. work, study, housework, family or leisure activities)
☐ I have no problems with performing my usual activities
☐ I have some problems with performing my usual activities
☐ I am unable to perform my usual activities

References

1 May M, Gompels M, Sabin C. Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK collaborative HIV cohort study. J Int AIDS Soc 2012; 15(Suppl 4): 18078.
2 Public Health England. HIV in the United Kingdom: 2014 report. Public Health England, UK, 2014.
3 UNAIDS. AIDS by the numbers. UNAIDS Corporate Publications, http://www.unaids.org/en/resources/documents/2015/AIDS_by_the_numbers_2015, 2013.
4 Chambers LA, Wilson MG, Rueda S, Gogolishvili D, Qiyun Shii M, Rourke SB for the Positive Aging Review Team. Evidence informing the intersection of HIV, aging and health: a scoping review. AIDS Behav 2014; 18: 661–675.

5 O’Keefe KJ, Scheer S, Chen MJ, Hughes AJ, Pipkin S. People fifty years or older now account for the majority of AIDS cases in San Francisco, California, 2010. AIDS Care 2013; 25: 1145–1148.
6 Balderson BH, Grothaus L, Harrison RG, McCoy K, Mahoney C, Catz S. Chronic illness burden and quality of life in an aging HIV population. AIDS Care 2012; 25: 451–458.
7 Harding R, Molloy T, Easterbrook P, Frame K, Higginson IJ. Is antiretroviral therapy associated with symptom prevalence and burden? Int J STD AIDS 2006; 17: 400–405.
8 Harding R, Lampe FC, Norwood S et al. Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect 2010; 86: 520–524.
9. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. Clin Sci 2003; 17: 1179–1193.

10. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 10–14.

11. Thomas J, Doherty SM. HIV infection – a risk factor for osteoporosis. J Acquir Immune Defic Syndr 2003; 33: 281–291.

12. Marzolini C, Back D, Weber R et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 2107–2111.

13. Capeau J. Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin Infect Dis 2011; 68: 1354–1359.

14. Smith RD, Delpech VC, Brown AE, Rice BD. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010; 24: 2109–2115.

15. Oursler KK, Goulet JL, Leaf DA et al. Association of comorbidity with physical disability in older HIV-infected adults. AIDS Patient Care STDS 2006; 20: 782–791.

16. Stoff DM. Mental health research in HIV/AIDS and aging: problems and prospects. AIDS 2004; 18: S3–S10.

17. Miners A, Phillips A, Kreif N et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV 2014; 1: e32–40.

18. Nokes KM, Coleman CI, Hamilton MJ et al. Age-related effects on symptom status and health-related quality of life in persons with HIV/AIDS. Appl Nurs Res 2011; 24: 10–16.

19. Frain J, Barton-Burke M, Bachman J et al. A comparison of medication management between older and younger adults living with HIV. J Assoc Nurses AIDS Care 2014; 25: 414–26.

20. Speakman A, Rodgér A, Phillips AN et al. The ‘Antiretrovirals, Sexual Transmission Risk and Attitudes’ (ASTRA) study. Design, methods and participant characteristics. PLoS ONE 2013; 8: e77230.

21. Webber K, Davis AN. Validity of the memorial symptom assessment scale-short form psychological subscales in advanced cancer patients. J Pain Symptom Manage 2011; 42: 761–767.

22. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606–613.

23. Spitzer RL, Kroenke K, Williams JB. A brief measure for assessing generalised anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092–1097.

24. Rabin R, de Charrro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med 2001; 33: 337–343.

25. Lifson AR, Grandits GA, Gardner EM et al. Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16(Suppl 1): 88–96.

26. Siegel K, Lekas HM, Schrimshaw EW, Brown-Bradley CJ. Strategies adopted by late middle-age and older adults with HIV/AIDS to explain their physical symptoms. Psychol Health 2011; 26: 41–62.

27. Solomon P, O’Brien K, Wilkins S, Gervais N. Aging with HIV and disability: the role of uncertainty. AIDS Care 2014; 26: 240–5.

28. King SD, Orel N. Midlife and older gay men living with HIV/AIDS: the influence of resiliency and psychosocial stress factors on health needs. J Gay Lesbian Soc Serv 2012; 24: 346–370.

29. Emlet CA, Tozay S, Raveis VH. “I’m not going to die from the AIDS”: resilience in aging with HIV disease. Gerontologist 2011; 51: 101–111.

30. Heckman TG, Heckman BD, Kochman A, Sikkema KJ, Suhr J, Goodkin K. Psychological symptoms among persons 50 years of age and older living with HIV disease. Aging Ment Health 2002; 6: 121–128.

31. Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS 2004; 18: 43–48.

32. Heckman TG, Kochman A, Sikkema KJ. Depressive symptoms in older adults living with HIV disease: application of the chronic illness quality of life model. J Ment Health Aging 2002; 8: 267–279.

33. Havlik RJ. Multimorbidity and depression in HIV-infected older adults. Psychol AIDS Exchange News 2014. http://www.apa.org/pi/aids/resources/exchange/2014/01/multi-morbidity.aspx.

34. Vance DE, Robinson FP. Reconciling successful aging with HIV: a biopsychosocial overview. J HIV AIDS Soc Serv 2004; 3: 59–78.

35. Kahana E, Kahana B. Successful aging among people with HIV/AIDS. J Clin Epidemiol 2001; 54: S53–S56.

36. Wagnild G, Young H. Development and psychometric evaluation of the resilience scale. J Nurs Meas 1993; 1: 163–177.

37. Vance DE, Struzick TC, Masten J. Hardiness, successful aging, and HIV: implications for social work. J Gerontol Soc Work 2008; 51: 260–283.

38. Skevington SM. Is quality of life poorer for older adults with HIV/AIDS? International evidence using the WHOQOL-HIV. AIDS Care 2012; 24: 1219–25.

39. Holmes WC, Shea JA. A new HIV/AIDS-targeted quality of life (HAT-QoL) instrument: development, reliability, and validity. Med Care 1998; 36: 138–154.

40. Vance DE, McGuinness T, Musgrove K, Orel NA, Fazeli PL. Successful aging and the epidemiology of HIV. Clinical
interventions in aging. Clin Interv Aging 2011; 6: 181–192.

41 Cuevas JE, Vance DE, Viamonte SM, Lee SK, South JL. A comparison of spirituality and religiousness in older and younger adults with and without HIV. J Spiritual Ment Health 2010; 12: 273–287.

42 Rauer AJ, Sabey A, Jensen JF. Growing old together: compassionate love and health in older adulthood. J Soc Pers Relat 2013; 31: 677–696.

43 Catz SL, Heckman TG, Kochman A, Dimarco M. Rates and correlates of HIV treatment adherence among late middle-aged and older adults living with HIV disease. Psychol Health Med 2001; 6: 47–58.

44 Greenbaum AH, Wilson LE, Keruly JC, Moore RD, Gebo KA. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 2008; 22: 2331–2339.

45 Grow SL, Yeung P, Towers A, Alpass F, Stephens C. The impact of mobility on quality of life among older persons. J Aging Health 2013; 25: 723–736.